Potential clinical benefits and cost savings of universal leucocyte-depletion of blood components.
Murphy
M F
MF
National Blood Service, John Radcliffe Hospital, Oxford, UK.
D016913:Blood Component Transfusion / Q000191:economics / Q000295:instrumentation / Q000379:methods / Q000592:standards*; D002469:Cell Separation / Q000191:economics*; D003362:Cost-Benefit Analysis; D007562:Creutzfeldt-Jakob Syndrome / Q000191:economics / Q000517:prevention & control*; D006077:Government Agencies; D017408:Guidelines as Topic; D006402:Hematologic Diseases / Q000191:economics / Q000628:therapy; D006801:Humans; D007430:Intraoperative Care / Q000191:economics; D007902:Length of Stay; D007962:Leukocytes / Q000737:chemistry; D011182:Postoperative Care / Q000191:economics; D011183:Postoperative Complications / Q000191:economics / Q000517:prevention & control; D012449:Safety; D013514:Surgical Procedures, Operative; D065227:Transfusion Reaction; D006113:United Kingdom